Eli Lilly and Company (NYSE:LLY) Receives Buy Rating from Guggenheim

Key Points

• Guggenheim analysts reiterated a "buy" rating for Eli Lilly and Company (NYSE:LLY) with a target price of $948.00, indicating a potential upside of 14.74% from the current stock price.
• The stock has a consensus rating of Moderate Buy, with 15 analysts rating it as a Buy and an average price target of $948.06.
• Eli Lilly reported strong quarterly earnings with $6.31 earnings per share, significantly exceeding the consensus estimate of $5.59, and a revenue increase of 37.6% compared to the previous year.

Eli Lilly and Company (NYSE:LLY - Get Free Report)'s stock had its "buy" rating reissued by analysts at Guggenheim in a report issued on Thursday,Benzinga reports. They currently have a $948.00 target price on the stock. Guggenheim's target price suggests a potential upside of 14.74% from the stock's current price.

Several other equities research analysts also recently weighed in on LLY. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a report on Sunday, August 17th. Morgan Stanley decreased their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a report on Friday, October 3rd. The Goldman Sachs Group increased their price target on Eli Lilly and Company from $876.00 to $879.00 and gave the stock a "buy" rating in a report on Friday, October 10th. Berenberg Bank reaffirmed a "hold" rating and set a $830.00 price target (down from $970.00) on shares of Eli Lilly and Company in a report on Wednesday, September 17th. Finally, Weiss Ratings reaffirmed a "hold (c+)" rating on shares of Eli Lilly and Company in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $948.06.

Eli Lilly and Company Price Performance

LLY stock opened at $826.20 on Thursday. The company has a market capitalization of $781.97 billion, a P/E ratio of 54.00, a PEG ratio of 1.16 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The business has a 50 day simple moving average of $745.96 and a 200-day simple moving average of $766.28. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. The business had revenue of $15.56 billion during the quarter, compared to the consensus estimate of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company's revenue was up 37.6% compared to the same quarter last year. During the same period in the prior year, the company earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Insider Activity

In other Eli Lilly and Company news, EVP Daniel Skovronsky purchased 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $634.40 per share, with a total value of $634,400.00. Following the purchase, the executive vice president owned 137,660 shares in the company, valued at approximately $87,331,504. This represents a 0.73% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of the firm's stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the purchase, the director owned 9,402 shares in the company, valued at $6,013,143.12. The trade was a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 4,514 shares of company stock worth $2,894,841 in the last quarter. Corporate insiders own 0.13% of the company's stock.

Institutional Trading of Eli Lilly and Company

A number of hedge funds have recently added to or reduced their stakes in LLY. PNC Financial Services Group Inc. lifted its stake in shares of Eli Lilly and Company by 97.5% in the 1st quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. Laurel Wealth Advisors LLC lifted its stake in shares of Eli Lilly and Company by 78,621.2% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company's stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares in the last quarter. Norges Bank acquired a new position in shares of Eli Lilly and Company in the 2nd quarter valued at about $8,827,714,000. Nuveen LLC acquired a new position in shares of Eli Lilly and Company in the 1st quarter valued at about $4,613,912,000. Finally, Vanguard Group Inc. lifted its stake in shares of Eli Lilly and Company by 6.7% in the 1st quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.